Gracevit (sitafloxacin) / Daiichi Sankyo - LARVOL DELTA

Successful treatment of inducible macrolide-resistant Mycobacterium abscessus subspecies abscessus surgical site infection after cosmetic surgery. (PubMed, IDCases) - "Treatment was initiated with combination antimicrobial therapy, including imipenem/cilastatin, amikacin, and tigecycline for 4 weeks, followed by clofazimine and sitafloxacin for 11 months as maintenance therapy. After 12 months of treatment, the fistula closed, and no recurrence occurred during follow-up. This case highlights the importance of considering MAA in surgical site infections following cosmetic surgery and suggests that individualized combination antimicrobial therapy based on susceptibility testing may lead to successful outcomes in macrolide-resistant extrapulmonary MAA."

Journal • Aesthetic Medicine • Dermatology • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Successful treatment of Mycobacterium abscessus pulmonary disease with limited resection and perioperative chemotherapy containing clofazimine: a case report. (PubMed, Respir Med Case Rep) - "Clarithromycin susceptibility shifted from susceptible on Day 3 to resistant on Day 14. Combination antimicrobial therapy was initiated with imipenem/cilastatin, amikacin, azithromycin, clofazimine, and sitafloxacin...The patient completed a 12-month course of antimicrobial therapy and remains recurrence-free at 30 months based on CT follow-up. The only notable side effect of chemotherapy was grade 2 skin hyperpigmentation, which was attributed to clofazimine."

Journal • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Comparison of sitafloxacin monotherapy versus doxycycline plus rifampicin for acute uncomplicated human brucellosis: a multicenter, randomized, open-label, non-inferiority trial. (PubMed, Lancet Reg Health West Pac) - P4 | "This work was supported by the National Key Research and Development Program of China (2023YFC2308800)and the Natural Science Foundation of Shandong Province (ZR2023MH169). ChiCTR2300072703."

Head-to-Head • Journal • Monotherapy

In vitro antibacterial activity of gepotidacin in combination with other antimicrobial agents against Neisseria gonorrhoeae isolates. (PubMed, Antimicrob Agents Chemother) - "Synergy and antagonism were evaluated using fractional inhibitory concentration (FIC) and FIC index (FICI) results for gepotidacin and comparator agents (azithromycin, cefixime, ceftriaxone, gemifloxacin, sitafloxacin, gentamicin, spectinomycin, doxycycline, and lefamulin). The evaluation of FICI showed no antagonistic or synergistic interactions, while the evaluation of individual FIC values revealed strain- and agent-specific synergistic or additive effects."

Journal • Preclinical • Infectious Disease

Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. (PubMed, Antibiotics (Basel)) - "Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123...Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens...Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show..."

Journal • Review • Acne Vulgaris • Dental Disorders • Dermatology • Infectious Disease • Periodontitis • Vaginitis

Contribution of ParC -and GyrA- mutations to fluoroquinolone treatment failures in Mycoplasma genitalium: a systematized review. (PubMed, Sex Transm Dis) - "Sitafloxacin was significantly more effective than moxifloxacin in the presence of resistance mutations. This descriptive review provides compilated and preliminary data regarding the contribution of parC and gyrA mutations to fluoroquinolone resistance, to be considered in diagnostic assay designs. This may ultimately lead therapeutic decision-making guidance."

Journal • Infectious Disease

Peritoneal dialysis-related peritonitis caused by Mycobacterium brisbanense: A case report and literature review. (PubMed, IDCases) - "Despite initial empirical treatment with cefazolin and ceftazidime for co-isolated bacteria (Staphylococcus warneri and Kocuria marina), the symptoms worsened...The patient was successfully treated by PD-catheter removal and intravenous administration of amikacin, imipenem/cilastatin, and oral azithromycin for 40 days, followed by oral azithromycin and sitafloxacin for 153 days. M. brisbanense is a potential opportunistic pathogen in PD-related peritonitis that requires tailored antimicrobial therapy."

Journal • Chronic Kidney Disease • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Nontuberculous Mycobacterial Disease • Renal Disease • Respiratory Diseases

TREATMENT OF PEDIATRIC MYCOBACTERIUM ABSCESSUS PULMONARY INFECTION INCLUDING SITAFLOXACIN: A CASE REPORT (ESPID 2026) - "Based on drug susceptibility testing, an induction regimen consisting of amikacin, linezolid, imipenem/cilastatin, and azithromycin was administered for two months...Regular blood tests and electrocardiograms performed during treatment revealed no significant adverse effects. Learning Points/Discussion Sitafloxacin may serve as a safe and effective oral treatment option for pediatric M. abscessus infections when conventional therapeutic options are limited."

Case report • Clinical • Infectious Disease • Nontuberculous Mycobacterial Disease • AFP

Antimicrobial resistance crisis in STIs: Gonorrhea and M. genitalium on the brink of untreatability. (PubMed, New Microbes New Infect) - "Data sources included WHO reports, peer-reviewed studies (2010-2024), and phase II/III trials of new drugs like zoliflodacin and gepotidacin...Dual resistance to ceftriaxone/azithromycin is emerging...Third-line options (pristinamycin, sitafloxacin) have limited availability and effectiveness...Investment in new antibiotics and alternative approaches (e.g., doxycycline prophylaxis) is crucial. Global public health efforts are needed to curb resistance and prevent untreatable STIs."

Journal • Review • Infectious Disease

The Role of Combination Antibiotic Therapy in Combatting Drug-Resistant Acinetobacter baumannii Infections: A Systematic Review of Randomised Control Trials. (PubMed, Antibiotics (Basel)) - "Current RCT evidence does not support routine use of combination therapy over monotherapy for drug-resistant A. baumannii infections, particularly in septic ICU populations where host factors dominate outcomes. Future trials should focus on early-stage or non-sepsis infections, incorporate molecular resistance profiling, and evaluate emerging agents such as sulbactam-durlobactam to guide precision therapy."

Journal • Review • Infectious Disease • Septic Shock

A Review on the Progress and Strategies of Helicobacter pylori Eradication Therapy for Patients With Penicillin Allergy. (PubMed, Gastroenterol Res Pract) - "The classic quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is commonly recommended due to its relatively satisfactory efficacy and sufficient research evidence (81.4%, 95% CI 78.6%-84.2%). The mean eradication rate for other regimens containing new drugs such as minocycline, cefuroxime, sitafloxacin, vonoprazan, and rifabutin is well (> 80%)...Although new drugs and regimens have emerged, their efficacy needs confirmation through more high-quality, large-scale clinical studies to identify the optimal eradication therapy regimen. Individualized treatment, particularly therapies tailored based on the results of genetic antibiotic resistance testing, represents an important direction for future research."

Journal • Review • Allergy • Immunology • Infectious Disease

Killing of stationary staphylococcus aureus within microaggregates and macrophages by free sitafloxacin and sugar, or as carrier-free nanodrug. (PubMed, Colloids Surf B Biointerfaces) - "They accumulate in macrophages, reducing intracellular bacteria by 2 log10 without any cytotoxic effect. This novel nanosystem co-delivers antibiotic and sugar without inert carriers, demonstrating antimicrobial activity, biocompatibility, and delayed release, offering potential for targeting persistent bacterial infections."

Journal • Infectious Disease

SUCCESSFUL TREATMENT WITH CLOFAZIMINE FOR MACROLIDE-RESISTANT MYCOBACTERIUM ABSCESSUS INFECTION IN A PERITONEAL DIALYSIS PATIENT (ISN-WCN 2026) - "The patient transitioned to hemodialysis following catheter removal 11 days after symptom onset, with extensive surgical debridement and a 6-week combination antibiotic therapy including imipenem-cilastatin, amikacin and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine and sitafloxacin for 4 months...Our case represents the first successful treatment of macrolide-resistant M. abscessus PD-associated infection using clofazimine-containing combination therapy, demonstrating clofazimine as a potential therapeutic option in combination therapy. Multimodal therapy including early catheter removal, extensive surgical debridement, and prolonged multidrug antimicrobial regimens containing clofazimine may represent a viable..."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Polycystic Kidney Disease • Renal Disease • Respiratory Diseases • Tuberculosis • CRP

SUCCESSFUL SALVAGE OF A PERITONEAL DIALYSIS CATHETER IN A CASE OF NONTUBERCULOUS MYCOBACTERIAL INFECTION (ISN-WCN 2026) - "Despite topical gentamicin, the discharge worsened. On Day -8, ultrasound showed a peri-catheter hypoechoic area consistent with TI, a swab for culture was obtained, and oral cefaclor was started...Empiric therapy with linezolid, amikacin, and clarithromycin was started on Day 1...Current guidance highlights NTM among atypical causes of refractory ESI, encourages individualized salvage strategies including exit-site relocationConclusion In PD patients with refractory ESI/TI, clinicians should obtain early AFB cultures and species identification to guide management. Early exit-site revision/debridement with an oral dual regimen of clarithromycin and sitafloxacin can salvage the catheter and maintain PD when cardiac dysfunction and obesity limit alternatives, demonstrating a practicalt success where evidence remains limited."

Clinical • Nontuberculous mycobacteria • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Obesity • Respiratory Diseases • Thrombocytopenia

Successful treatment with clofazimine for macrolide-resistant Mycobacterium abscessus infection in a peritoneal dialysis patient: A case report and literature review. (PubMed, Perit Dial Int) - "Initial management included early catheter removal, extensive surgical debridement, and 6 weeks of combination antibiotic therapy, including imipenem-cilastatin, amikacin, and clarithromycin, achieving clinical cure. However, the infection recurred after 5 months, necessitating retreatment with debridement and an antibiotic regimen including imipenem-cilastatin, amikacin, azithromycin, and clofazimine for 4 weeks, followed by a continuation regimen with amikacin, clofazimine, and sitafloxacin for 4 months...Based on a literature review of 67 cases of M. abscessus PD-associated infections, all six cases treated with clofazimine achieved clinical cure, but there were no reports on cases of macrolide-resistant M. abscessus treated with clofazimine. Our case represents the first successful clofazimine treatment of macrolide-resistant M. abscessus PD-associated infection, demonstrating clofazimine as a potentially effective oral antibiotic option in combination therapy,..."

Journal • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Effects of hydroxybisphosphonates-conjugated sitafloxacin on fracture healing and skeletal growth in mice. (PubMed, JBMR Plus) - "To address this, we assessed HBCS effects vs placebo, zoledronic acid (ZA) positive control known to inhibit osteoclasts and increase fracture callus and growth plate bone volume, and hydroxy-phenyl-ethane-hydroxy-bisphosphonate (HPHBP), the bisphosphonate component of HBCS, using a murine closed femur fracture model, and on intramembranous and endochondral ossification in the proximal tibia of 12-wk-old mice. However, HPHBP and HBCS increased growth plate bone volume over total volume (BV/TV) concomitant with a decrease in osteoclasts, while ZA further increased total bone volume and BV/TV with a dramatic increase in osteoclasts. Collectively, these data demonstrate that while HBCS decreases osteoclast numbers in vivo, it does not inhibit fracture healing or normal bone growth in mice."

Journal • Preclinical • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance (PubMed, Dermatologie (Heidelb)) - "N. gonorrhoeae is showing increasing resistance to penicillins, tetracyclines, and fluoroquinolones; furthermore, there is a growing reduction in susceptibility to the macrolide antibiotic azithromycin. Resistance rates to ceftriaxone, the current first-line therapy in many international treatment guidelines, and to cefixime, the peroral treatment option frequently used in outpatient settings, remain very low in German-speaking countries. For M. genitalium, increasing resistance is observed primarily to macrolides and, less commonly, to fluocinolones; cases of infections with combined resistance to both antimicrobial classes have been reported and regularly require the use of reserve antibiotics such as pristinamycin or sitafloxacin. Enhanced surveillance, molecular resistance testing, avoidance of overdiagnosis, rational and responsible antibiotic use (preventing overtreatment), and the development and implementation of new antimicrobial agents are..."

Journal • Review • Infectious Disease

A single-center culture-based study of Helicobacter pylori in Kazakhstan with regional meta-analysis of prevalence and antibiotic resistance. (PubMed, Front Microbiol) - "Resistance rates among 86 isolates were 87.2% to metronidazole, 33.7% to clarithromycin, and 3.5% to amoxicillin; no resistance was detected to minocycline or sitafloxacin. Absence of resistance to minocycline and sitafloxacin supports their use in rescue regimens. These findings highlight the urgent need for national surveillance, updated treatment guidelines, and integration of molecular resistance monitoring to improve evidence-based management of H. pylori in Central Asia."

Journal • Retrospective data • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Third-Line and Later Susceptibility-Guided Helicobacter pylori Eradication Therapies: A Multicenter Study of Vonoprazan-Amoxicillin-Sitafloxacin/Rifabutin Regimens. (PubMed, J Clin Med) - " Susceptibility-guided vonoprazan-based regimens from the third-line treatment onward achieved high eradication and tolerability in a multicenter cohort. This approach may offer a valuable treatment option for patients with refractory H. pylori infections."

Clinical • Journal • Infectious Disease

Clinical epidemiology and management challenges of genital Mycoplasma and Ureaplasma infections: A retrospective observational study at a Japanese urban clinic. (PubMed, Sex Health) - "In a Tokyo clinical setting, M. genitalium was the most prevalent species and the primary driver of symptoms, whereas M. hominis and Ureaplasma spp. frequently suggest colonization. Management remains challenging due to suboptimal cure rates and poor follow-up adherence. These findings support a tiered diagnostic strategy that prioritizes exclusion of major sexually transmitted infections and emphasizes species-specific management."

Journal • Observational data • Retrospective data • Infectious Disease

A PAN-USR TB Multi-Center Trial (clinicaltrials.gov) - P3 | N=610 | Recruiting | Sponsor: Shenzhen Third People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium avium Complex Pulmonary Disease. (PubMed, Cureus) - "Prior treatment regimens primarily involved azithromycin- or clarithromycin-based therapies, supplemented with sitafloxacin, with a median treatment duration of five years. These findings highlight the challenges of managing refractory MAC pulmonary disease in a real-world setting and emphasize the importance of considering patient characteristics, including radiographic patterns and baseline health, when initiating ALIS therapy. Adverse events were frequent but manageable with appropriate monitoring and adjustments."

Journal • Real-world evidence • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium Avium complex Pulmonary Disease (APSR 2025) - "Prior to ALIS initiation, patients had received macrolide-based regimens (azithromycin or clarithromycin) with sitafloxacin for a median duration of five years. While generally tolerable, the adverse event profile warrants careful monitoring. These findings highlight the importance of patient selection and potentially earlier ALIS intervention, particularly in patients with NB pattern disease."

Clinical • Real-world • Real-world evidence • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease. (PubMed, BMC Pulm Med) - No abstract available

Journal • Pulmonary Disease • Respiratory Diseases

In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. (PubMed, ACS Omega) - "This study evaluates the in vitro activity of common and potential antimicrobials, including Trimethoprim-sulfamethoxazole, Amikacin, Oxazolidinones (Linezolid, Tedizolid, Contezolid), Fluoroquinolones (Moxifloxacin, Levofloxacin, Sitafloxacin), Rifampicin, and Fidaxomicin against 51 clinical Nocardia isolates. These findings highlight the need for tailored treatment strategies based on species-specific susceptibility and resistance profiles and suggest Fidaxomicin and Sitafloxacin as promising options. Further clinical validation is warranted to optimize therapeutic outcomes."

Journal • Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis